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Despite its use in more than one half million men in the United 
States alone, androgen deprivation therapy for prostate cancer 
remains controversial (1). Whereas it is clearly indicated for palli-
ation of symptomatic metastatic disease, the benefits are unclear 
when it is given as primary treatment for localized tumors, a sce-
nario for which it is nevertheless commonly prescribed (2–5). 
Androgen deprivation therapy is also associated with a host of 
adverse effects, such as osteoporosis and fractures, cardiovascular 
disease, and diabetes (4,6). Even when androgen deprivation is 
used as an adjuvant to radiation in men with localized but high-
risk, or locally advanced prostate cancer, a setting for which most 
clinical trials have demonstrated improved overall survival, a post 
hoc analysis of one trial showed a trend toward worse overall sur-
vival in some subgroups of men (7). Ongoing examination of the 
risks of androgen deprivation therapy is therefore a priority.
We recently described a case of monozygotic twins who were 
diagnosed with colon cancers after receiving androgen deprivation 
therapy for prostate cancer (8). We speculated that shared biological 
mechanisms in the men may have contributed to the development of 
colon cancer in the setting of androgen deprivation because data 
from various studies suggest that androgens exert protective effects 
against colorectal carcinogenesis (9–13). Furthermore, androgen 
deprivation therapy has been associated with development of hyper-
insulinemia, diabetes mellitus, and obesity, all of which are known 
risk factors for colorectal cancer (14,15). To explore this issue further, 
we used the Surveillance, Epidemiology, and End Results (SEER) 
and Medicare-linked database to assess the risk of colorectal cancer 
associated with androgen deprivation in the form of orchiectomy or 
treatment with gonadotropin-releasing hormone (GnRH) agonists in 
a large population-based sample of men with prostate cancer.
Methods
Data Sources
The SEER–Medicare database links two large population-based 
sources of data that together provide information about older adults 
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 Background  Androgen deprivation with gonadotropin-releasing hormone (GnRH) agonists or orchiectomy is a common but 
controversial treatment for prostate cancer. Uncertainties remain about its use, particularly with increasing rec-
ognition of serious side effects. In animal studies, androgens protect against colonic carcinogenesis, suggesting 
that androgen deprivation may increase the risk of colorectal cancer.
  Methods  We identified 107 859 men in the linked Surveillance, Epidemiology, and End Results (SEER)–Medicare database 
who were diagnosed with  prostate  cancer  in  1993  through  2002, with  follow-up  available  through  2004.  The 
primary outcome was development of colorectal cancer, determined  from SEER  files on second primary can-
cers.  Cox  proportional  hazards  regression was  used  to  assess  the  influence  of  androgen  deprivation  on  the 
outcome, adjusted for patient and prostate cancer characteristics. All statistical tests were two-sided.
  Results  Men  who  had  orchiectomies  had  the  highest  unadjusted  incidence  rate  of  colorectal  cancer  (6.3  per  1000 
person-years; 95% confidence interval [CI] = 5.3 to 7.5), followed by men who had GnRH agonist therapy (4.4 per 
1000 person-years; 95% CI = 4.0 to 4.9), and men who had no androgen deprivation (3.7 per 1000 person-years; 
95% CI = 3.5  to 3.9). After adjustment  for patient and prostate cancer characteristics,  there was a statistically 
significant  dose–response  effect  (Ptrend  =  .010) with  an  increasing  risk  of  colorectal  cancer  associated with  in-
creasing  duration  of  androgen  deprivation.  Compared  with  the  absence  of  these  treatments,  there  was  an 
increased risk of colorectal cancer associated with use of GnRH agonist therapy for 25 months or longer (hazard 
ratio [HR] = 1.31, 95% CI = 1.12 to 1.53) or with orchiectomy (HR = 1.37, 95% CI = 1.14 to 1.66).
 Conclusion  Long-term androgen deprivation therapy for prostate cancer  is associated with an  increased risk of colorectal 
cancer.
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also been independently associated with the development of co-
lorectal cancer (15).
We assessed androgen deprivation therapy using previously 
published and validated methods (4,23). It was categorized either 
as the receipt of GnRH agonists or as the occurrence of orchiec-
tomy. Because in some patients low testosterone levels can persist 
for several months beyond discontinuation of GnRH agonist 
therapy, we performed sensitivity analyses in which we assumed 
that patients were on androgen deprivation therapy for a total of 
either 6 months or 12 months following a monthly depot injection 
(24). In both cases, the results were similar to the main analysis and 
are not presented.
The primary outcome was the development of colorectal can-
cer, as determined from SEER files on second primary cancers. 
Characteristics of the colorectal cancers—stage, grade, and prox-
imal vs distal site (ie, cecum to splenic flexure vs descending colon 
to rectum)—were also derived from SEER files (Table 1). Because 
patients with cancer can be missed by use of the tumor registries, 
we also performed an analysis in which we additionally identified 
colorectal cancer cases using diagnosis codes on Medicare claims 
based on previously published algorithms (25,26).
Statistical Analyses
For all analyses, patients had to survive at least 6 months after 
diagnosis of prostate cancer to be included. Patients who devel-
oped colorectal cancer in the first 6 months following diagnosis of 
prostate cancer (n = 264) were excluded because it was felt that 
those cancers were unlikely to be related to the androgen depriva-
tion therapy.
with newly diagnosed cancer in the United States (16). The SEER 
program is administered by the National Cancer Institute and con-
sists of regional and state-based tumor registries located through-
out the country. It represented approximately 14% of the United 
States population until 2001 and 26% thereafter. Medicare is a 
federal program that covers health services for 97% of persons aged 
65 years and older. It provides data in the form of claims submitted 
by providers for reimbursement, which include information on di-
agnoses and the services, testing, or procedures rendered.
Study Subjects
For this study, we selected data for all men aged 67 years or older 
who were registered in SEER with a new diagnosis of prostate 
cancer in the years 1993 through 2002. Follow-up information 
was available through 2004. By setting the minimum age to 67 
instead of 65 years, we allowed for the presence of at least 2 years 
of Medicare claims before prostate cancer diagnosis for assessment 
of baseline comorbidities. To ensure completeness of the Medicare 
claims information, patients who were not enrolled in both 
Medicare part A and part B for the 24 months before and 
6 months after their cancer diagnosis (n = 20 734), those who 
were members of a Health Maintenance Organization (n = 
44 698), and those who were diagnosed by autopsy or on a death 
certificate (n = 2 408) were excluded, leaving a final study sample 
of 107 859 men.
Study Definitions
Definitions for all study variables are provided in table format 
(Table 1). Data concerning patient characteristics (age, race, 
socioeconomic status, marital status, region of residence, comor-
bidity, and delivery of routine preventive care) and cancer charac-
teristics (grade and stage) were derived from SEER and/or 
Medicare files as previously described (4,17,18).
We also specifically examined several potential confounding 
factors. Delivery of routine preventive care may be a confounder 
because it can influence both the stage and grade of prostate 
cancer at diagnosis and therefore likelihood of androgen depriva-
tion therapy use, as well as likelihood of developing colorectal 
cancer. This was assessed by using Medicare claims to examine 
the number of visits to a primary care physician and whether a 
lower gastrointestinal endoscopy was performed in the 12–24 
months before diagnosis of the prostate cancer. Differential rates 
of medical work-up in patients who did or did not undergo 
androgen deprivation could result in possible detection bias; 
therefore, use of lower gastrointestinal endoscopy after prostate 
cancer diagnosis was also examined in a time-dependent manner. 
Obesity may also be an important confounder because it is a risk 
factor for the development of colorectal cancer, and although 
data are conflicting, it has been associated with higher grade or 
advanced stage prostate tumors that are more likely to be treated 
with androgen deprivation therapy (19–21). Obesity was identi-
fied using diagnosis codes on the Medicare claims (defined in 
Table 1). Although this approach misses a substantial proportion 
of obese patients, it still provides an estimate of the relative rates 
of obesity as a function of androgen deprivation exposure. 
Patients with diabetes before diagnosis of prostate cancer were 
also identified as a proxy for obesity (22) and because diabetes has 
CONTEXT AND CAVEATS
Prior knowledge
Androgen deprivation therapy, via orchiectomy or use of gonadotropin-
releasing hormone (GnRH) agonists, is commonly used for prostate 
cancer. The authors examined whether it might be associated with 
a risk for colorectal cancer.
Study design
Surveillance,  Epidemiology,  and  End  Results  (SEER)  data  for 
107 859  American  men  with  prostate  cancer  were  examined  for 
presence or absence of androgen deprivation therapy and for inci-
dence of secondary colorectal cancers.
Contribution
Men who had orchiectomies or GnRH agonist therapy had a higher 
incidence of colorectal cancer than men who did not have androgen 
deprivation. Risk increased with increasing duration of this therapy.
Implications
Long-term  androgen  deprivation  therapy  puts  men  at  increased 
risk for colorectal cancer.
Limitations
Efforts were made to adjust for age, socioeconomic status, medical 
visits, and obesity, but other confounding is possible. All data were 
for Medicare patients with prostate cancer, so conclusions could be 
different for younger men or those without prostate cancer.
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Incidence rates of colorectal cancer in person-years during 
treatment with GnRH agonists, after orchiectomy, or during pe-
riods of no androgen deprivation were calculated with correspond-
ing 95% confidence intervals (CI) assuming a Poisson distribution, 
and the results were stratified by patient characteristics. Survival 
analyses to calculate hazard ratios (HRs) were performed using 
Cox proportional hazards regression with androgen deprivation as 
a time-dependent covariate for the main analysis, and with time to 
occurrence of colorectal cancer as the dependent variable. Patients 
were censored at death, loss of Medicare part A or B coverage, 
switch to a Health Maintenance Organization coverage or end of 
the study period (December 31, 2004). Using androgen deprivation 
as a time-dependent covariate allowed men to contribute risk in-
formation to the androgen deprivation group for the period after 
initiation of GnRH agonist treatment or after undergoing orchiec-
tomy, and to the no androgen deprivation group, either before the 
Table 1. Definition of the study variables*
Variable Data source Definition
Patient characteristics  
  Age SEER Age at diagnosis in years
  Race SEER White, black, white Hispanic, other
  Marital status SEER Married at time of diagnosis or not
  Place of residence SEER SEER geographic region: San Francisco, Connecticut, Michigan, Hawaii, Iowa, New Mexico,  
  Seattle, Utah, Georgia, San Jose (CA), Los Angeles
  Socioeconomic status:  
    income
2000 US Census Available only at patient zip code level: median income in zip code of residence
  Socioeconomic status:  
    education
2000 US Census Available only at patient zip code level: percentage of adults in zip code with <12 years of  
  education
  Comorbidity index Medicare Based on Klabunde modification of the Charlson index using inpatient, outpatient, and physician 
  Medicare claims. The Charlson index is derived from a scoring system based on a count of  
  certain comorbid diagnoses. Klabunde adaptation allows identification of comorbid diagnoses  
  from Medicare inpatient and outpatient claims
  No. of primary care  
    physician visits
Medicare and  
  AMA Masterfile
Calculated from number of physician visits on separate days as defined by the presence of an  
  outpatient physician claim (excluding emergency room visits) for a face-to-face evaluation  
  using †CPT codes of the form 99xxx. The UPIN associated with the claim was linked to AMA 
  data to identify physician specialty as primary care (family practice, general internal medicine,  
  general practice, or geriatricians)
  Lower gastrointestinal  
    endoscopy
Medicare Any claim for ICD-9 procedure codes 45.23, 45.24, CPT codes 45330, 45355, 45378, or HCPCS 
  codes G0104, or G0105
  Diabetes mellitus Medicare One inpatient claim or two outpatient–physician claims in any position with ICD-9 diagnosis 
  codes 250.xx, 357.2,362.0-362.0x,366.41,790.2
  Obesity Medicare Any claim for ICD-9 diagnosis codes 278.00, 278.01, 783.1, 783.6
Cancer characteristics  
    (at diagnosis) 
  Stage SEER Prostate cancer: using clinical T stage from SEER Extent of Disease coding; categorized as T1,  
  T2, T3, T4, unknown. Colorectal cancer: using SEER historical staging system; categorized as  
  in situ, localized, regional or distant spread, or unknown
  Grade SEER Prostate or colorectal cancer: SEER grading information; categorized as well differentiated,  
  moderately differentiated, poorly differentiated, undifferentiated, or unknown
  Site (colorectal only) SEER Based on site code definitions; categorized as cecum, appendix, ascending colon, hepatic  
  flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, large intestine  
  not otherwise specified, rectosigmoid junction and rectum
Androgen deprivation  
  Orchiectomy Medicare Any claim with CPT codes 54520, 54521, 54522, 54530, or 54535; or ICD-9 procedure code 
  62.4
  GnRH agonist Medicare Any claim with HCPCS codes J9202, J1950, J9217, J9218, or J9219
  Months of GnRH 
    agonist therapy
Medicare Calculated from each instance of a GnRH agonist HCPCS J-code noted on separate days.  
  GnRH agonists are generally administered as depot injections with the dosage given depend 
  ing on the intended duration of the regimen; usually once a month, once every 3-month or  
  once every 4-month regimens. The intended duration for a given injection was determined  
  first from the unit designation (1, 3, or 4) of the “carrier miles/time/units/serv count” field of  
  the physician services claims or if unavailable, from the “revenue center unit count” field of  
  the outpatient claims
Study outcome  
  Incident colorectal  
    cancer
SEER or Medicare From SEER: site codes indicating colorectal cancer diagnosis following diagnosis of prostate  
  cancer. From Medicare claims algorithm: ICD-9 diagnosis codes 153.x, 154.0, 154.1, 230.3, 
  230.4 in any position in at least one inpatient claim or at least two (on different days) outpa 
  tient or physician claims with no claims in preceding 2 years
*  AMA = American Medical Association; CPT = Current Procedural Terminology; GnRH = gonadotropin-releasing hormone; HCPCS = Healthcare Common 
Procedure Coding System;  ICD-9 = International Classification of Diseases, Ninth revision; SEER = Surveillance, Epidemiology and End Results; UPIN = unique 
physician identification number.
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initiation of androgen deprivation or if they never received andro-
gen deprivation during the study period. Men who stopped GnRH 
agonist therapy were assumed to continue to contribute informa-
tion to the GnRH agonist group for the remainder of study 
follow-up (re-analysis assigning these men back to the no androgen 
deprivation group did not substantially alter the results). To assess 
for a dose–response effect, GnRH agonist use was categorized 
based on the duration of its administration to men who received 
1–4, 5–12, 13–24, or 25 months or more of therapy over the study 
period (orchiectomy was considered separately). For example, a 
man who received 3 months of GnRH agonist therapy would start 
to contribute information to the GnRH agonist 1- to 4-month 
group. If at some point he went on to receive an additional 3 
months of therapy (total of 6 months of treatment), he would 
then start to contribute information to the GnRH agonist 5- to 
12-month group. Tests were performed for interaction between 
age, race, prostate tumor stage, or prostate tumor grade and the 
androgen deprivation variable on the outcome of colorectal can-
cer; none of these associations were statistically significant (using 
age as a continuous variable, and race, grade, and stage as cate-
gorical variables with cut points as presented in Table 2). In a 
separate analysis, additional Cox modeling was performed using 
androgen deprivation as a fixed rather than time-dependent 
covariate and examining GnRH agonist or orchiectomy use 
limited to the first year after diagnosis of prostate cancer. This 
model yielded similar results to the main model and the findings 
are therefore not presented. In this model, the proportionality 
assumption for the effect of androgen deprivation was verified by 
determining that the logarithm of the baseline cumulative haz-
ard rates and the Schoenfeld residuals were proportional with 
follow-up time.
Because this study is observational, propensity score methods 
were used in an additional analysis to improve the balance of mea-
sured confounders between the groups with and without androgen 
deprivation. Briefly, the propensity scores were generated from a 
logistic regression model that predicted use of androgen depriva-
tion over the study period. The propensity score quintile was then 
entered as an independent variable in the Cox model described 
above along with any covariates that remained statistically signifi-
cantly imbalanced between the groups with and without androgen 
deprivation within the propensity quintiles.
All analyses were performed using SAS v.9.1 (SAS institute, 
Cary, NC). All statistical tests were two-sided, with P values less 
than .05 considered to be statistically significant. The study proto-
col was approved by the Institutional Review Board at the 
University of Michigan.
Results
The primary study sample comprised a total of 107 859 men aged 
67 years and older with prostate cancer who were diagnosed from 
January 1, 1993, to December 31, 2002. Of those men, 55 901 
(51.8%) received androgen deprivation during the study period: 
50 097 (46.4%) received GnRH agonists and 5804 (5.4%) had 
undergone orchiectomy. Baseline patient and prostate tumor char-
acteristics, with patients stratified into three groups based on 
whether they received GnRH agonist treatment, orchiectomy, or 
no androgen deprivation during the study follow-up, show that 
patients who received androgen deprivation (GnRH agonists or 
orchiectomy) were older (P < .001; t test for comparison of any use 
of androgen deprivation vs no androgen deprivation) and more 
likely to have clinical stage T4 tumors (P < .001; x2 for comparison 
of any use of androgen deprivation vs no androgen deprivation) or 
tumors with poorly differentiated or undifferentiated histology 
(P < .001; x2 for comparison of any use of androgen deprivation vs 
no androgen deprivation) (Table 2). The frequency of obesity and 
diabetes before the diagnosis of prostate cancer was similar in the 
three groups, although it was most common in the GnRH agonist 
group and least common in the orchiectomy group.
We calculated the unadjusted incidence rates of colorectal can-
cer during GnRH agonist therapy, after orchiectomy, or during 
periods of no androgen deprivation, stratified by various patient 
and prostate cancer characteristics (Table 3). The incidence of 
colorectal cancer was highest among men who had orchiectomies, 
at 6.3 cancers per 1000 person-years (95% CI = 5.3 to 7.5), inter-
mediate among men taking GnRH agonist therapy, at 4.4 cancers 
per 1000 person-years (95% CI = 4.0 to 4.9), and lowest among 
men with no androgen deprivation at 3.7 cancers per 1000 person-
years (95% CI = 3.5 to 3.9). This pattern was generally consistent 
within strata of patient and prostate cancer characteristics.
We tabulated the stage, grade, and proximal vs distal colon site 
of the 2035 colorectal tumors that were diagnosed over the study 
period as a function of androgen deprivation exposure (Table 4). 
There was a statistically significant difference across the three 
groups (no androgen deprivation, GnRH agonist, and orchiec-
tomy) in the proportion of colorectal tumors that were poorly 
differentiated or undifferentiated (P = .013; x2 test), with orchiec-
tomy patients having the highest proportion of such tumors. 
Tumor stage and site were not associated with androgen depriva-
tion exposure.
The risk of developing colorectal cancer associated with 
androgen deprivation was assessed with a Cox regression model 
adjusted for patient and prostate cancer variables (Table 5). 
Subjects were followed for a mean of 59.4 months after diagnosis. 
The risk of colorectal cancer increased with increasing duration 
of GnRH agonist therapy over the study period and was highest 
for men who underwent orchiectomy (Ptrend = .01). Compared 
with men receiving no androgen deprivation, there was a gra-
dient of increasing risk of colorectal cancer, from men who 
received 13–24 months of GnRH agonist therapy (adjusted HR = 
1.19, 95% CI = 1.00 to 1.41), to men who received 25 months or 
more of GnRH agonist therapy (adjusted HR = 1.31, 95% CI = 
1.12 to 1.53) and, to men who underwent orchiectomy (adjusted 
HR = 1.37, 95% CI = 1.14 to 1.66). Other factors that were asso-
ciated with colorectal cancer in the model included older age, 
black race, residence in a zip code with lower rates of high school 
graduation, or a diagnosis of diabetes mellitus before diagnosis of 
prostate cancer. Use of lower gastrointestinal endoscopy after 
diagnosis of prostate cancer (entered as a time-dependent covari-
ate) was associated with a statistically significantly lower risk of 
colorectal cancer.
When these men were included, the results from the Cox 
model remained similar to the main analysis presented in Table 5: 
compared with men who received no androgen deprivation, 
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Table 2. Distribution of patient and prostate tumor characteristics in men who received gonadotropin-releasing hormone (GnRH) agonist 
treatment, orchiectomy, or no androgen deprivation over study follow-up
Characteristic No.
Exposure to androgen deprivation over study follow-up
None, % GnRH agonist therapy, % Orchiectomy, %
Total 107 859 51 958 50 097 5804
Age, y*      
  67–69 19 899 23.3 14.5 9.3
  70–74 36 413 37.0 31.7 22.8
  75–79 28 708 23.7 29.4 28.3
  ≥80 22 839 16.0 24.4 39.7
Race      
  White 86 524 80.9 79.6 80.3
  Black 10 286 10.0 9.2 8.4
  Hispanic 4598 4.0 4.3 5.6
  Other or unknown 6451 5.2 6.9 5.8
Married      
  No 34 428 30.2 33.5 33.8
  Yes 73 431 69.8 66.5 66.2
Prostate tumor grade†      
  Well differentiated 9013 11.6 5.3 5.8
  Moderately differentiated 66 389 67.5 57.6 41.7
  Poorly differentiated or undifferentiated 24 268 13.1 30.0 41.6
  Unknown 8189 7.7 7.1 10.9
Prostate tumor clinical stage‡      
  T1 32 925 36.0 26.8 14.4
  T2 56 458 52.2 54.0 39.6
  T3 4126 2.9 4.4 7.6
  T4 6248 2.2 7.0 27.6
  Unknown 8102 6.7 7.9 10.8
Zip code education, % of adults with <12 y education      
  <9.4 25 710 25.3 22.9 18.8
  8.4 to <14.8 26 305 24.2 24.4 26.0
  14.8–23.5 25 778 23.6 24.0 25.4
  ≥23.5 25 739 22.8 24.8 25.5
  Unknown 4327 4.1 3.9 4.2
Zip code median income      
  <$36 000 27 065 24.3 25.3 30.4
  $36 000 to <$46 000 23 889 22.1 21.9 24.8
  $46 000 to <$60 000 25 897 24.5 23.6 22.5
  ≥$60 000 26 681 25.0 25.3 18.0
  Unknown 4327 4.1 3.9 4.2
Comorbidity index      
  0 79 412 81.5 78.9 78.5
  1 19 388 12.3 14.1 14.3
  2 6001 4.0 4.8 2.8
  ≥3 3058 2.2 2.3 2.6
Diabetes mellitus in the period 24 mo before diagnosis      
  No 90 412 84.7 82.6 86.5
  Yes 17 447 15.3 17.4 13.5
Obesity in the period 24 mo before diagnosis      
  No 105 156 97.7 97.2 98.6
  Yes 2703 2.3 2.8 1.4
Number of primary care physician visits in the period 12–24 mo  
    before diagnosis
     
  0 41 231 40.0 35.4 46.9
  1 15 031 14.3 13.6 13.3
  2 12 427 11.7 11.5 10.0
  ≥3 39 170 33.9 39.5 29.9
Lower gastrointestinal endoscopy in the period 12–24 mo before  
    diagnosis
     
  No 101 182 93.4 93.9 96.3
  Yes 6677 6.6 6.1 3.7
*  Patients with androgen deprivation (any form) were older than those without (P <.001, two-sided t test).
†  Patients with androgen deprivation (any form) were more likely to have poorly differentiated or undifferentiated tumors (P < .001, two-sided x2 test).
‡  Patients with androgen deprivation (any form) were more likely to have stage T4 tumors than those without (P < .001, two-sided x2 test).
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Table 3. Unadjusted incidence rates of colorectal cancer for men on gonadotropin-releasing hormone (GnRH) agonist therapy, after 
orchiectomy, or with no androgen deprivation, stratified by patient and prostate cancer characteristics
Characteristic
Incidence rate of colorectal cancer per 1000 person-years (95% CI)
No androgen deprivation GnRH agonist therapy Orchiectomy
Total 3.7 (3.5 to 3.9) 4.4 (4.0 to 4.9) 6.3 (5.3 to 7.5)
Age, y    
  67–69 3.0 (2.6 to 3.4) 3.2 (2.2 to 4.5) 6.3 (3.5 to 10.6)
  70–74 3.4 (3.2 to 3.7) 3.9 (3.1 to 4.8) 6.3 (4.4 to 8.9)
  75–79 4.1 (3.7 to 4.5) 4.6 (3.8 to 5.5) 5.6 (3.9 to 7.7)
  ≥80 5.0 (4.4 to 5.6) 5.3 (4.4 to 6.3) 6.9 (5.2 to 9.0)
Race    
  White 3.6 (3.4 to 3.8) 4.6 (4.1 to 5.2) 6.4 (5.3 to 7.7)
  Black 5.3 (4.6 to 6.1) 5.0 (3.5 to 6.8) 6.5 (3.1 to 12.0)
  Hispanic 3.6 (2.7 to 4.7) 4.1 (2.3 to 6.9) 4.4 (1.4 to 10.2)
  Other or unknown 2.4 (1.8 to 3.1) 1.8 (0.9 to 3.2) 6.2 (2.7 to 12.1)
Married    
  No 3.8 (3.4 to 4.1) 3.8 (3.1 to 4.6) 5.8 (4.2 to 7.9)
  Yes 3.7 (3.5 to 3.9) 4.7 (4.2 to 5.4) 6.6 (5.3 to 8.0)
Prostate tumor grade*    
  Well differentiated 4.3 (3.7 to 5.0) 4.2 (2.6 to 6.4) 4.0 (1.5 to 8.7)
  Moderately differentiated 3.6 (3.3 to 3.8) 4.4 (3.8 to 5.0) 7.4 (5.8 to 9.3)
  Poorly differentiated or undifferentiated 3.8 (3.3 to 4.3) 4.4 (3.7 to 5.3) 5.8 (4.3 to 7.7)
Prostate tumor clinical stage†    
  T1 3.4 (3.1 to 3.8) 3.9 (3.0 to 4.9) 3.7 (1.9 to 6.4)
  T2 3.8 (3.5 to 4.0) 4.4 (3.8 to 5.1) 7.2 (5.6 to 9.2)
  T3 4.3 (3.4 to 5.4) 4.6 (2.8 to 7.0) 6.3 (3.3 to 11.0)
  T4 4.0 (2.7 to 5.7) 3.6 (2.3 to 5.4) 7.0 (4.9 to 9.9)
Zip code education,‡ % of adults with less than 12 y education    
  < 8.4 3.2 (2.8 to 3.5) 4.2 (3.3 to 5.3) 5.6 (3.6 to 8.3)
  8.4 to <13.3 3.6 (3.2 to 4.0) 4.2 (3.3 to 5.2) 6.0 (4.2 to 8.3)
  13.4 to 20.3 4.2 (3.8 to 4.6) 4.7 (3.8 to 5.7) 6.4 (4.4 to 8.9)
  ≥20.4 4.3 (3.9 to 4.8) 4.6 (3.8 to 5.7) 7.1 (5.0 to 9.8)
Zip code median income‡    
  <$37 500 4.3 (3.9 to 4.8) 4.7 (3.9 to 5.7) 6.4 (4.6 to 8.6)
  $37 500 to <$47 500 3.8 (3.4 to 4.2) 4.1 (3.2 to 5.1) 7.0 (5.0 to 9.5)
  $47 500 to <$62 000 3.8 (3.4 to 4.2) 4.4 (3.5 to 5.5) 4.7 (3.0 to 7.1)
  ≥ $62 000 3.3 (3.0 to 3.7) 4.4 (3.6 to 5.5) 7.1 (4.8 to 10.2)
Comorbidity index    
  0 3.7 (3.5 to 3.9) 4.0 (3.6 to 4.6) 6.5 (5.4 to 7.9)
  1 3.9 (3.4 to 4.4) 5.3 (4.2 to 6.6) 4.9 (2.9 to 7.8)
  2 3.7 (2.7 to 4.7) 5.3 (3.5 to 7.7) 6.0 (2.2 to 13.0)
  ≥3 2.4 (1.4 to 3.8) 5.8 (3.1 to 10.0) 10.3 (3.3 to 24.0)
Diabetes mellitus in the period 24 mo before diagnosis    
  No 3.6 (3.4 to 3.8) 4.3 (3.8 to 4.8) 6.4 (5.3 to 7.7)
  Yes 4.2 (3.7 to 4.8) 4.9 (3.8 to 6.3) 5.6 (3.1 to 9.2)
Obesity in the period 24 mo before diagnosis    
  No 3.7 (1.7 to 3.9) 4.4 (4.0 to 4.9) 6.3 (5.3 to 7.5)
  Yes 2.6 (1.7 to 3.9) 4.5 (2.0 to 8.5) 7.2 (0.9 to25.9)
Number of primary care physician visits in the period 12–24  
    mo before diagnosis
  0 3.8 (3.5 to 4.1) 5.0 (4.3 to 5.9) 6.1 (4.7 to 7.9)
  1 3.6 (3.1 to 4.1) 2.9 (1.9 to 4.1) 5.6 (3.3 to 8.9)
  2 3.6 (3.1 to 4.2) 4.4 (3.2 to 6.0) 5.8 (3.1 to 9.9)
  ≥3 3.7 (3.4 to 4.0) 4.3 (3.6 to 5.1) 7.2 (5.2 to 9.6)
Lower gastrointestinal endoscopy in the period 12–24 mo  
    before diagnosis
  No 3.8 (3.6 to 4.0) 4.5 (4.0 to 5.0) 6.4 (5.3 to 7.6)
  Yes 2.5 (1.9 to 3.1) 3.3 (1.9 to 5.4) 4.9 (1.3 to 12.5)
*  Results for 8189 cases with unknown prostate tumor grade not presented.
†  Results for 8102 cases with unknown prostate tumor stage not presented.
‡  Results for 4327 cases with missing zip code information not presented.
there was an increased risk of colorectal cancer in men who 
received 13–24 months of GnRH agonist therapy (adjusted HR = 
1.24, 95% CI = 1.08 to 1.42), in men who received 25 months or 
more of GnRH agonist therapy (adjusted HR = 1.24, 95% CI = 
1.08 to 1.41) and in men who underwent orchiectomy (adjusted 
HR = 1.34, 95% CI = 1.14 to 1.57).
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Because radiation therapy for prostate cancer has been associ-
ated in some studies with the development of rectal cancer, we 
performed additional analyses to exclude this as a contributing 
factor to the observed results. We repeated the Cox model after 
excluding patients who received radiation therapy at any time fol-
lowing diagnosis of prostate cancer. The results were essentially 
unchanged (adjusted HR for development of colorectal cancer for 
patients who received ≥25 months of GnRH agonist therapy = 
1.35, 95% CI = 1.12 to 1.63; for patients who underwent orchiec-
tomy, adjusted HR = 1.36, 95% CI = 1.10 to 1.69). Findings were 
also similar when the original Cox model was performed to exam-
ine development of colon cancer only, with rectal cancers ex-
cluded: for patients who received 25 months or more of GnRH 
agonist therapy, adjusted hazard ratio = 1.27 (95% CI = 1.06 to 
1.52) and for men who underwent orchiectomy, adjusted hazard 
ratio = 1.30 (95% CI =1.04 to 1.63). The corresponding adjusted 
hazard ratios for the development of rectal cancer only (colon 
cancers excluded) were 1.42 (95% CI = 1.04 to 1.93) in patients 
who received 25 months or more of GnRH agonist therapy and 
1.54 (95% CI = 1.08 to 2.20) in patients who underwent 
orchiectomy.
Finally, in a propensity score–adjusted Cox model that was 
designed to improve the balance of measured confounders between 
the groups with and without androgen deprivation, the results 
were again similar to the main findings in Table 5. The adjusted 
hazard ratios were 1.28 (95% CI = 1.09 to 1.49) for men who 
received 25 months or more of GnRH agonist therapy, and 1.42 
(95% CI = 1.18 to 1.72) for men who underwent orchiectomy.
Additional analyses were performed to examine potential issues 
of mediation and residual confounding. Because diabetes mellitus 
is a known risk factor for colorectal cancer and androgen depriva-
tion therapy has been associated with the development of diabetes 
mellitus (6), we explored whether the observed effect of androgen 
deprivation on colorectal cancer was mediated by the development 
of diabetes. We limited the cohort of patients to those without 
diabetes before diagnosis of prostate cancer and performed the 
Cox model in Table 5 with and without the inclusion of a time-
dependent variable denoting an incident diagnosis of diabetes after 
diagnosis of prostate cancer. The association between androgen 
deprivation therapy and colorectal cancer was unaffected by the 
inclusion of the incident diabetes diagnosis variable (data not 
shown), suggesting that diabetes was not mediating the effect of 
androgen deprivation on colorectal cancer risk in our model. 
Because obesity (defined by body mass index of 30 or more) is a 
strong risk factor for colorectal cancer (19,20), we explored the 
potential effect of confounding by obesity on our findings. 
Although we incorporated a Medicare claims–based obesity vari-
able into the model in Table 5, this variable likely grossly under-
estimates the true prevalence of obesity due to poor capture of this 
condition by Medicare claims. We therefore performed sensitivity 
analyses (27) assuming the presence of an obesity variable with a 
prevalence of 30% in the group without androgen deprivation 
[based on the known prevalence of obesity among elderly males in 
the United States (28)]. Our results were robust to assumptions of 
up to a 50% higher rate of obesity in the androgen deprivation 
groups and hazard ratios of 1.5 to 2.0 for risk of colorectal cancer 
associated with obesity (results shown in Supplementary Table 1, 
available online).
Discussion
This study provides strong evidence to link androgen deprivation 
therapy in the setting of prostate cancer to an increased risk of 
colorectal cancer. After adjustment for a number of potentially 
confounding variables, there was a 30%–40% increase in the rate 
of colorectal cancer among men with prostate cancer who were 
treated with androgen deprivation therapy compared with men 
with prostate cancer who were not.
There was also a statistically significant dose–response effect, 
with a higher risk of colorectal cancer with an increasing duration 
of androgen deprivation, providing support that the observed 
association between androgen deprivation and colorectal cancer in 
the setting of prostate cancer may be causal. The study findings also 
have biological plausibility. Indeed, androgen receptors are present 
in both normal and malignant human colonic tissues (29,30), and in 
various animal studies, administration of androgens protects 
against colon carcinogenesis, whereas androgen ablation promotes 
it (9,10,12,13). The vast majority of colorectal cancers are related 
to abnormal activation of Wnt/b-catenin/T-cell factor signaling 
(31), and there is a large body of evidence that indicates that andro-
gen receptor activation can strongly repress this signaling in colon 
cancer cells (32–35). This effect is related to competition between 
Table 4. Characteristics of colorectal cancers as a function of receipt of androgen deprivation*
Androgen  
deprivation
No. colorectal  
cancer patients
Tumor stage† Tumor grade‡ Site of tumor§
% Localized P║
% Poorly differentiated  
or undifferentiated P║ % Distal P║
None 1048 48.0 .073 21.4 .013 53.1 .489
GnRH agonist 849 51.8   18.6   55.6
Orchiectomy 138 41.5   30.6   52.2
*  GnRH = gonadotropin-releasing hormone; SEER = Surveillance, Epidemiology, and End Results.
†   Based on SEER historical staging system, categorized as in situ or localized, regional, or distant spread; for the 1701 patients diagnosed from SEER files and 
having stage information available.
‡  Based on SEER grading system, categorized as well differentiated, moderately differentiated, poorly differentiated or undifferentiated; for the 1676 patients diag-
nosed from SEER files and having grade information available.
§  Site of tumor categorized as proximal (cecum through splenic flexure) vs distal (descending colon through rectum) based on SEER files.
║  All P values are two-sided and are based on x2 tests for differences in the proportion of colorectal tumors with the characteristic of interest across the androgen 
deprivation exposure groups.
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Table 5. Risk of colorectal cancer associated with androgen deprivation therapy*
Characteristic
Unadjusted colorectal cancer risk Adjusted colorectal cancer risk
P║HR,†‡ (95% CI) HR,‡§ (95% CI)
Androgen deprivation therapy    
  None 1.00 (referent) 1.00 (referent) .002
  GnRH agonist 1–4 mo 1.01 (0.87 to 1.17) 1.07 (0.92 to 1.24)
  GnRH agonist 5–12 mo 1.11 (0.97 to 1.27) 1.12 (0.97 to 1.30)
  GnRH agonist 13–24 mo 1.29 (1.09 to 1.52) 1.19 (1.00 to 1.41)
  GnRH agonist ≥ 25 mo 1.48 (1.27 to 1.72) 1.31 (1.12 to 1.53)
  Orchiectomy 1.68 (1.41 to 2.01) 1.37 (1.14 to 1.66)
Age (for every 5 y older)   1.18 (1.13 to 1.23) <.001
Race    
  White   1.00 (referent) <.001
  Black   1.24 (1.06 to 1.46)
  Hispanic   0.90 (0.71 to 1.15)
  Other or unknown   0.52 (0.40 to 0.68)
Married    
  No   1.00 (referent) .014
  Yes   1.13 (1.03 to 1.25)
Prostate tumor grade    
  Well differentiated   1.00 (referent) .794
  Moderately differentiated   0.93 (0.80 to 1.08)
  Poorly differentiated or undifferentiated   0.92 (0.78 to 1.09)
  Unknown   0.92 (0.74 to 1.14)
Prostate tumor clinical stage    
  T1   1.00 (referent) .374
  T2   1.11 (1.00 to 1.23)
  T3   1.16 (0.94 to 1.44)
  T4   1.10 (0.87 to 1.39)
  Unknown   1.10 (0.91 to 1.31)
Zip code education, % adult less than 12 y education    
  <9.4   1.00 (referent) .003
  8.4 to <14.8   1.08 (0.94 to 1.24)
  14.8–23.5   1.24 (1.06 to 1.46)
  ≥23.5   1.26 (1.02 to 1.54)
Zip code median income    
  <$36 000   1.00 (referent) .860
  $36 000 to <$46 000   0.95 (0.83 to 1.10)
  $46 000 to <$60 000   1.00 (0.84 to 1.18)
  ≥$60 000   1.01 (0.82 to 1.25)
Comorbidity index    
  0   1.00 (referent) .766
  1   1.04 (0.91 to 1.19)
  2   0.97 (0.77 to 1.23)
  ≥3   0.85 (0.58 to 1.24)
Lower gastrointestinal endoscopy performed after diagnosis    
  No   1.00 (referent) < .001
  Yes   0.64 (0.56 to 0.72)
Diabetes mellitus in the period 24 mo before diagnosis    
  No   1.00 (referent) .030
  Yes   1.15 (1.01 to 1.30)
Obesity in the period 24 mo before diagnosis    
  No   1.00 (referent) .269
  Yes   0.83 (0.59 to 1.16)
*  CI = confidence interval; GnRH = gonadotropin-releasing hormone; HR = hazard ratio.
†  Based on a Cox regression model with time to occurrence of colorectal cancer as the dependent variable and only androgen deprivation entered as a time-dependent 
covariate with the outcome censored at death, loss or switch away from Medicare coverage or end of the study period.
‡  Excluding patients who developed colorectal cancer or died within 6 months of diagnosis of prostate cancer.
§  Based on a Cox regression model with time to occurrence of colorectal cancer as the dependent variable, androgen deprivation entered as a time-varying covariate, and 
age at time of prostate cancer diagnosis, race, marital status, prostate tumor grade, prostate tumor stage, year of diagnosis, SEER region of residence, percentage with 
less than 12 years of education in zip code of residence, median income in zip code of residence, number of primary care physician visits in the period 12–24 months 
before diagnosis of prostate cancer, whether lower gastrointestinal endoscopy was performed in the period 12–24 months before diagnosis of prostate cancer, presence 
of diabetes mellitus in the period 24 months before diagnosis, presence of obesity in the period 24 months before diagnosis and performance of lower gastrointestinal 
endoscopy after diagnosis (as a time-dependent covariate) entered as independent variables. Outcome was censored at death, loss or switch away from Medicare part A 
or B coverage or at end of study period. Results for SEER region, year of diagnosis, number of primary care physician visits in the period 12–24 months before diagnosis 
of prostate cancer and whether lower gastrointestinal endoscopy was performed in the period 12–24 months before  diagnosis of prostate cancer are not presented.
║  P values are two-sided and are based on the Cox model and test whether any differences exist within categories of the independent variables.
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androgen receptors and T-cell factor for binding to b-catenin, and 
it can be reversed by anti-androgen administration. In support of 
this line of evidence, androgen receptor expression levels in colo-
rectal tumors have been shown to be lower than those found in 
samples of normal mucosa (29,30). Our findings are also consistent 
with the results of a large clinical trial in postmenopausal women 
that showed that estrogen plus progestin replacement reduces the 
risk of colorectal cancer. The authors of that study hypothesized 
that the protective effect may have been related in part to correc-
tion of hyperinsulinemia in estrogen-deficient women (36). 
Hyperinsulinemia and its correlates, type 2 diabetes mellitus, obe-
sity, and metabolic syndrome are strong risk factors for colorectal 
cancer (15). Postulated mechanisms for this effect include the 
ability of insulin to stimulate proliferation and delay apoptosis in 
colon cancer cells (37,38). Although we were unable to demonstrate 
that new onset diabetes mediates the effect of androgen deprivation 
on risk of colorectal cancer in our analysis, the hyperinsulinemia 
and obesity known to develop in men receiving androgen depriva-
tion therapy for prostate cancer may nevertheless be another poten-
tial causal mechanism for our study findings (14).
Given the observational nature of this study, confounding 
factors that may account for the apparent association between 
androgen deprivation therapy and colorectal cancer must be con-
sidered. Older age is associated both with use of androgen depri-
vation therapy for prostate cancer and with risk of colorectal 
cancer (39,40). Lack of routine preventive care or lower socioeco-
nomic status may lead to later stage presentation of prostate 
cancer, which increases the likelihood of treatment with androgen 
deprivation, and may also be associated with occurrence of colo-
rectal cancer (41,42). However, the association between androgen 
deprivation and colorectal cancer persisted after adjustment for 
age and measures of socioeconomic status and preventive care. 
Increased medical surveillance resulting from frequent health-
care contacts in men receiving GnRH agonist injections may have 
led to an increase in colorectal cancer diagnoses. However, if this 
were the case, a higher proportion of early-stage colorectal 
tumors would have been expected in the androgen deprivation 
groups, which was not observed (Table 3). In addition, the risk of 
colorectal cancer associated with androgen deprivation remained 
after adjustment for ongoing performance of lower gastrointesti-
nal endoscopies following the diagnosis of prostate cancer. 
Several other factors associated with colorectal cancer, such as 
family history, use of nonsteroidal anti-inflammatory drugs, or a 
history of smoking or heavy alcohol use, could not be assessed in 
the database. However, as these are not plausibly related to use of 
androgen deprivation therapy for prostate cancer, they would not 
be confounders in the analysis. Finally, obesity may be an impor-
tant confounder because it is known to increase the risk of colo-
rectal cancer in men, and although controversial, has in some 
studies been associated with higher grade or advanced stage pros-
tate tumors, which are more likely to be treated with androgen 
deprivation therapy (21,43,44). We examined the degree to which 
there was imbalance in rates of baseline obesity or diabetes (as a 
proxy for obesity) as a function of androgen deprivation exposure 
using Medicare claims–based algorithms. Men who went on to 
receive GnRH agonists were somewhat more likely to be obese or 
diabetic when compared with men who never received androgen 
deprivation therapy, but the lowest rates were in men who 
received orchiectomy (Table 2). Despite the differences in rates of 
obesity between the GnRH agonist and orchiectomy groups, both 
were associated with an increased risk of colorectal cancer, 
making confounding by obesity less likely. However, given the 
limitations in the ability to assess obesity based on Medicare 
claims, we also performed sensitivity analyses to examine the 
potential impact of obesity on our findings. The association 
between androgen deprivation and colorectal cancer was robust to 
assumptions of as much as a 50% higher rate of obesity in the 
androgen deprivation groups. Nevertheless, in future studies on 
this issue, it will be important to collect detailed information on 
baseline obesity.
Beyond issues of confounding, there are other important lim-
itations of this study. Because the study used Medicare data, it 
was limited to an older cohort of patients. The association 
between androgen deprivation and colorectal cancer may be dif-
ferent in younger men. It is also important to note that this study 
was performed entirely among men with prostate cancer. It is 
conceivable that men with prostate cancer may be more suscep-
tible to the development of colorectal cancer. The expected inci-
dence of colorectal cancer in our study cohort (by matching to 
general population SEER data on age, sex, race, and calendar 
year) is 3.1 (95% CI = 2.8 to 3.4) per 1000 person-years, which is 
lower than the rate (3.7 per 1000 person-years) we observed in 
our “control” group of men with prostate cancer who did not 
receive androgen deprivation therapy. As such, caution is war-
ranted when extrapolating our findings outside the context of 
prostate cancer.
The study results have important implications for men with 
prostate cancer who are receiving or contemplating initiation of 
androgen deprivation therapy. Despite a moderate relative risk for 
colorectal cancer, the impact may nevertheless be large, given that 
hundreds of thousands of men are on androgen deprivation 
therapy for prostate cancer (1). Androgen deprivation continues 
to be used as a primary therapy for localized prostate cancers and 
for treatment of biochemical recurrence after radical prostatec-
tomy or radiation despite lack of convincing evidence of survival 
benefit (5,45). In both scenarios, the therapy is likely to be of a 
prolonged duration given the generally slow progression of 
disease. Even a small risk of developing a possibly lethal second 
cancer must be weighed carefully when androgen deprivation 
therapy is considered in scenarios where its benefits are unclear. 
However, the size of the study sample did not allow us to examine 
the impact of the diagnosed colorectal cancers in this study on 
overall mortality. Consequently, the study findings should not 
preclude use of androgen deprivation in settings where clinical 
trials have clearly shown improvements in overall survival. The 
study findings also highlight the importance of routine preventive 
care, such as screening for other cancers, in prostate cancer survi-
vors receiving androgen deprivation therapy. The diagnosis of 
prostate cancer may dominate the focus of medical care, to the 
detriment of other necessary aspects of care. For example, in 
colon and breast cancer settings, patients followed by both a pri-
mary care physician and a medical oncologist received a higher 
proportion of recommended preventive care as compared with 
those only followed by an oncologist (46,47). Men on androgen 
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deprivation therapy may therefore especially benefit from the 
continued involvement of a primary care physician in their care in 
addition to their cancer specialist.
A final point is that the study findings may have broader impli-
cations, beyond the field of prostate cancer. Androgen deficiency 
is now recognized as a relatively common occurrence in the male 
general population, with one estimate placing the prevalence at 
2.4 million men in the United States and incidence at nearly half a 
million a year (48). Whether the androgen deficiency seen in the 
general population predisposes importantly to colorectal cancer 
risk will need to be explored further. In addition, clinical trials of 
testosterone replacement should consider including colorectal 
cancer as an outcome.
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